Gastroenterology and Hepatology Clinical Trials

The following searchable list includes all the Division of Gastroenterology and Hepatology, Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Search Studies

Showing 1 to 5 of 5 entries

Previous1Next

Trials
Healthy Control Esophageal Registry and Biorepository This study is being done to compare how the esophagus and upper stomach work in people who have Scleroderma with symptoms of reflux disease or difficulty swallowing (dysphagia) to healthy controls. We will collect skin, esophageal and stomach biopsies (small pieces of tissue) to be used for several studies.… This study is being done to compare how the esophagus and upper stomach work in people who have Scleroderma with symptoms of reflux disease or difficulty swallowing (dysphagia) to healthy controls. We will collect skin, esophageal and stomach biopsies (small pieces of tissue) to be used for several studies. Eligibility CriteriaMust not be: - Obese (i.e. BMI ≥30) - Known medical illnesses that could affect esophageal function, gene expression or histology - Have a diagnosis of an eating disorder - Have a diagnosis of an autoimmune disease - A current or previous smoker (smoked >100 cigarettes in lifetime) - Have a history of alcohol abuse or addiction or score of 2 or higher on the CAGE questionnaire - Taking antacids and/or proton pump inhibitors for heartburn - Allergies to Fentanyl or Midolazam (sedatives used during endoscopy) - Allergies to Lidocaine (Lidocaine anesthetic jelly used during manometry). - Pregnant or nursing (hormones associated with pregnancy and lactation are known to affect esophageal function) Principal Investigator Carlson, Dustin Allan IRB number STU00096856 More Info Keywords healthy control scleroderma GERD scleroderma esophagus Copy Study URL to Clipboard Copy
Measuring copper parameters in Wilson's Disease using a novel assay The purpose of this study is to find out if a new test for patients with Wilson’s disease can accurately and reliably measure so-called free copper, also known as non-ceruloplasmin copper (NCC). Ceruloplasmin is a protein that helps transport copper from the liver and deliver copper to … The purpose of this study is to find out if a new test for patients with Wilson’s disease can accurately and reliably measure so-called free copper, also known as non-ceruloplasmin copper (NCC). Ceruloplasmin is a protein that helps transport copper from the liver and deliver copper to the rest of your body to maintain your health. In Wilson’s disease, ceruloplasmin levels are low and free copper levels are higher than normal, which can be controlled by taking your Wilson’s disease medications regularly. There is currently no approved test to measure NCC. Your doctor may use a combination of tests including a blood test to measure ceruloplasmin in order to calculate the NCC, but this is not accurate or reliable. Having a more reliable and accurate measurement of NCC may help your doctor, in the future, make better informed decisions about your treatment, including the dose of your medicine. Eligibility Criteria Inclusion: 1. Willing and able to give informed consent for participation in the study 2. Male or female patients, aged 18 years or older as of signing the Informed Consent Form (ICF) 3. Able and willing to comply with study procedures and requirements, as judged by the treating physician 4. Established diagnosis of Wilson’s Disease (Leipzig score >4) 5. Either newly diagnosed or with elevated liver enzymes (defined as ALT, AST ≥1.5xULN) or 24-hour urinary copper excretion outside of recommended ranges [chelation range 200-500mcg/24 hr; zinc < 100mcg/24 hr] 6. Adequate venous access to allow collection of blood samples Principal Investigator Cheung, Amanda Ching-Wun Location(s) Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT05783687IRB number STU00219339 More Info Email Sipich, Kimberly A Phone +1 312 694 1293 Copy Study URL to Clipboard Copy
Northwestern TIPS Research Study ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their … ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions. Eligibility Criteria Undergoing a Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement Subjects over the age of 18 able to provide consent or have a legally authorized representative to provide consent in the event the subject is unable to consent due to a transient clinical condition Principal Investigator Boike, Justin Richard Location(s) Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT03973372IRB number STU00208288 More Info Keywords TIPS Email Boike, Justin Richard Phone Copy Study URL to Clipboard Copy
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, … The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, macrophages produce proteins that activate the immune system to assist in tissue repair. However, there is evidence that in people with scleroderma, the macrophages behave abnormally and contribute to scarring in the lungs. Patients who participate in this study will: donate fluid collected from their lungs during a bronchoscopy (taken at the time they are already scheduled to have a bronchoscopy or during their scheduled endoscopy) give a blood sample give esophageal biopsies (taken during their scheduled endoscopy) as an option, give skin biopsies Eligibility Criteria At least 18 years old Meet criteria for systemic sclerosis Receive care at Northwestern Medicine in Rheumatology, Pulmonary & Critical Care, and/or Gastroenterology scleroderma clinics Plan to undergo a standard of care bronchoscopy or endoscopy at Northwestern or a research bronchoscopy through a separate Northwestern study Principal Investigator Perlman, Harris R Location(s) Map it 633 N. St. Clair St. Chicago, IL IRB number STU00207083 More Info Keywords systemic sclerosis scleroderma interstitial lung disease ILD SSc-ILD fibrosis SSc endoscospy bronchoscopy Email Soriano, Alexandra Phone +1 312 503 4958 Copy Study URL to Clipboard Copy
Treatment for Pruitis in Primary Biliary Cholangitis (PBC). Volixibat is an experimental treatment, meaning that it has not been approved by the US Food and Drug Administration (FDA) or any worldwide regulatory body. Volixibat is a medicine that lowers circulating bile acid levels (the amount of certain chemicals that are produced by the liver and are present in … Volixibat is an experimental treatment, meaning that it has not been approved by the US Food and Drug Administration (FDA) or any worldwide regulatory body. Volixibat is a medicine that lowers circulating bile acid levels (the amount of certain chemicals that are produced by the liver and are present in the blood) that are believed to lead to the itching in patients with PBC. There are no other medicines approved to treat itching in patients with PBC. Eligibility Criteria Male or female, age ≥18 years Primary Biliary Cholangitis Pruitis History of Elevated Alkaline Phosphatase Principal Investigator Boike, Justin Richard Location(s) Map it 675 N. Saint Clair St. Chicago, IL ClinicalTrials.gov IdentifierNCT05050136IRB number STU00218351 More Info Keywords PBC Pruitis Itching Email Gottstein, Jeanne H Phone +1 312 694 0264 Copy Study URL to Clipboard Copy

Showing 1 to 5 of 5 entries

Previous1Next

Gastroenterology and Hepatology Clinical Trials

Healthy Control Esophageal Registry and Biorepository

Measuring copper parameters in Wilson's Disease using a novel assay

Northwestern TIPS Research Study

Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis

Treatment for Pruitis in Primary Biliary Cholangitis (PBC).